Clinical profile of responders to adaptive servo-ventilation: a cluster analysis from the READ-ASV European cohort.

Jean-Louis Pépin¹, Raphael Heinzer², Sébastien Bailly³, Florent Lavergne⁴, Adam V Benjafield⁵, Susanne Fischer⁶, Holger Woehrle⁷, Michael Arzt⁸

¹University Grenoble Alpes, Inserm, CHU Grenoble Alpes, HP2, Grenoble, France. Electronic address: jpepin@chu-grenoble.fr.

²Centre d'Investigation et de Recherche sur le Sommeil, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland.

³University Grenoble Alpes, Inserm, CHU Grenoble Alpes, HP2, Grenoble, France.

⁴ResMed Science Center, Saint-Priest, France.

⁵Resmed Science Center, Sydney, NSW, Australia.

⁶Resmed Science Center, Munich, Germany.

⁷Sleep and Ventilation Center Blaubeuren, Lung Center Ulm, Ulm, Germany.

⁸Department of Internal Medicine II, University Hospital Regensburg, Regensburg, Germany.

PubMed DOI

Abstract

BACKGROUND: Adaptive servo-ventilation (ASV) effectively treats central sleep apnea (CSA), with or without coexisting obstructive sleep apnea (CSA-OSA). However, this is a diverse patient group, and the characteristics of patients who are most likely to benefit from ASV therapy, outside of traditional etiology-based subgroups, are unknown. OBJECTIVES: To identify clusters of ASV-treated patients…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.